FR3120794B1 - Composition pour injection comprenant un conjugué peptidique - Google Patents

Composition pour injection comprenant un conjugué peptidique Download PDF

Info

Publication number
FR3120794B1
FR3120794B1 FR2102600A FR2102600A FR3120794B1 FR 3120794 B1 FR3120794 B1 FR 3120794B1 FR 2102600 A FR2102600 A FR 2102600A FR 2102600 A FR2102600 A FR 2102600A FR 3120794 B1 FR3120794 B1 FR 3120794B1
Authority
FR
France
Prior art keywords
composition
peptide conjugate
injection
unsubstituted
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2102600A
Other languages
English (en)
Other versions
FR3120794A1 (fr
Inventor
Nicolas Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Beauty Care Solutions France SAS
Original Assignee
Rpm Dermatologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rpm Dermatologie filed Critical Rpm Dermatologie
Priority to FR2102600A priority Critical patent/FR3120794B1/fr
Priority to PCT/FR2022/050481 priority patent/WO2022195228A1/fr
Publication of FR3120794A1 publication Critical patent/FR3120794A1/fr
Application granted granted Critical
Publication of FR3120794B1 publication Critical patent/FR3120794B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition comprenant :a. au moins un conjugué peptidique de formule (I) suivante :R1-X1-X2-X3-X4-A1-R2 (I)dans laquelle :R1, étant du côté N-terminal, est un atome d’hydrogène, ou un groupement alkyle en C1-C50 linéaire ou ramifié, substitué ou non substitué,X1 est un condensat de (L)-sérine,X2 est un condensat de (L) et/ou (D) acide aspartique,X3 est un condensat de (L) et/ou (D) lysine, ,X4 est un condensat de (L) et/ou (D) proline,X4, ou X3 et X4, étant optionnellement absents,les liaisons reliant X1 à X2, X2 à X3 le cas échéant, et X3 à X4 le cas échéant, pouvant être des liaisons peptidiques ou pseudopeptidiques,A1 est une liaison covalente, un groupement NH ou un atome d’oxygène,R2, étant du côté C-terminal, est un atome d’hydrogène, ou un groupement alkyle en C1-C50 linéaire ou ramifié, substitué ou non substitué,R1 et R2 ne pouvant être conjointement des atomes d’hydrogène,ou l’un de ses sels physiologiquement acceptables, etb. au moins un vecteur choisi parmi les solutions aqueuses ou les biomatériaux biocompatibles de comblement.
FR2102600A 2021-03-16 2021-03-16 Composition pour injection comprenant un conjugué peptidique Active FR3120794B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR2102600A FR3120794B1 (fr) 2021-03-16 2021-03-16 Composition pour injection comprenant un conjugué peptidique
PCT/FR2022/050481 WO2022195228A1 (fr) 2021-03-16 2022-03-17 Composition pour injection comprenant un conjugué peptidique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2102600A FR3120794B1 (fr) 2021-03-16 2021-03-16 Composition pour injection comprenant un conjugué peptidique
FR2102600 2021-03-16

Publications (2)

Publication Number Publication Date
FR3120794A1 FR3120794A1 (fr) 2022-09-23
FR3120794B1 true FR3120794B1 (fr) 2023-11-24

Family

ID=76159521

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2102600A Active FR3120794B1 (fr) 2021-03-16 2021-03-16 Composition pour injection comprenant un conjugué peptidique

Country Status (2)

Country Link
FR (1) FR3120794B1 (fr)
WO (1) WO2022195228A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601678B1 (fr) 1986-07-18 1989-11-24 Inst Nat Sante Rech Med Peptides comprenant la sequence seryl-aspartyl-lysyl-prolyle, procede pour l'extraction du tetrapeptide correspondant, et applications, notamment a la protection de la moelle osseuse au cours de traitements anticancereux par la chimiotherapie
WO1997028183A1 (fr) 1996-02-01 1997-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Peptides inhibiteurs de la proliferation de cellules hematopoietiques
FR2872040B1 (fr) 2004-06-23 2006-09-22 Centre Nat Rech Scient Cnrse Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent antivieillissement et restructurant de la peau
FR2882256B1 (fr) * 2005-02-18 2007-05-25 Centre Nat Rech Scient Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent pour ralentir la chute des cheveux et/ou stimuler leur croissance
KR101110317B1 (ko) * 2009-06-30 2012-02-15 고려대학교 산학협력단 조직재생을 위한 티모신 베타-4 유래 Ａｃ-ＳＤＫＰ 펩타이드의 스마트 방출지지체
FR3047990B1 (fr) 2016-02-18 2020-12-25 Rpm Dermatologie Composition cosmetique cutanee comprenant un peptide sdkp ou un analogue de celui-ci
KR20180002228A (ko) * 2016-06-29 2018-01-08 세종대학교산학협력단 티모신-유래 Ac-SDKP를 유효성분으로 포함하는 방사선 치료 효능증진제
KR20220007875A (ko) * 2019-05-08 2022-01-19 앨러스틴 스킨케어, 인크. 멍듬 개선 및 피부를 젊어지게 하기 위한 조성물 및 방법
CN111658573A (zh) * 2020-06-17 2020-09-15 广州艾尔亿医药有限公司 一种用于再生医学美容的类人血清蛋白制剂
FR3112687A1 (fr) * 2020-07-23 2022-01-28 Rpm Dermatologie Kit de soin personnalisé et personnalisable pour la peau

Also Published As

Publication number Publication date
WO2022195228A1 (fr) 2022-09-22
FR3120794A1 (fr) 2022-09-23

Similar Documents

Publication Publication Date Title
Tiegs et al. Leukotriene-mediated liver injury
US20090099100A1 (en) Compositions and methods for treating amyloidosis
JP6934011B2 (ja) Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ １結合ペプチド
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
DE69429984T2 (de) In position 3 durch eine stickstoffgruppe substituierte 1,3-dihydroindol-2-on derivate als vasopressin und/oder ocytocin agonisten und/oder antagonisten
HUE026798T2 (en) The use of cell-permeable peptide inhibitors of the JNK signal transduction biosynthetic pathway for the treatment of various autoimmune diseases
AU4831899A (en) 5-HT1F agonists
GB2472138A (en) Cyclosporin-mitochondrial targeting group conjugates useful in the treatment of ischaemia/reperfusion injury and neurodegenerative diseases
FR3120794B1 (fr) Composition pour injection comprenant un conjugué peptidique
KR940001883A (ko) 2-(n-(2-아미노에틸)아미노)아세트산 유도체의 용도
CA3004641A1 (fr) Peptides cycliques ciblant l'integrine alpha-4-beta-7
EP1730190A2 (fr) Inhibition d'isoformes de cav3 et variants d'epissage $g(d)25b pour diagnostic et traitement de cancers
MA59661B1 (fr) Conjugués de médicament anticorps comprenant des dérivés d'ectéinascidine
EP1867661A1 (fr) Compositions et procédés pour amener d'anticorps du Ras activé dans des cellules
DE69930412D1 (de) Anti-(retro)virale konjugate von sacchariden und acetamidino- oder guanidinoverbindungen
BR0309283A (pt) Preparação lìquida compreendendo derivado de camptotecina e composição farmacêutica produzìvel por liofilização da preparação
SIEGERS Antidotal effects of dimethyl sulphoxide against paracetamol‐, bromobenzene‐, and thioacetamide‐induced hepatotoxicity
DK0526192T3 (da) hexapeptid
FR2870242A1 (fr) Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie.
FR3071850B1 (fr) Composition d’additifs pour carburant
Gardiner et al. Effects of the non‐peptide, non‐selective endothelin antagonist, bosentan, on regional haemodynamic responses to NG‐monomethyl‐L‐arginine in conscious rats
Miyauchi et al. Structure-activity relationships of sulfur-containing triazole antifungals
Panter et al. Biochemical changes and secondary injury from stroke and trauma
KR910009718A (ko) 프라디미신 유도체
BR0008479A (pt) Agonistas de 5-ht 1f

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220923

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: BASF BEAUTY CARE SOLUTIONS FRANCE SAS, FR

Effective date: 20231017

PLFP Fee payment

Year of fee payment: 4